Nabriva Therapeutics plc
NBRVF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$323
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $323.00 |
|---|---|
| Enterprise Value | $-1,255,677.00 |
| Earnings per Share | $-21.32 |
| Beta | -0.68 |
| Outstanding Shares | 3,231,000 |
Return
| Return on Equity | 1250.52% |
|---|---|
| Return on Assets | -223.87% |
| Return on Invested Capital | 1431.89% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | 0.0 |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | 0.09 |
| Enterprise Value to EBIT | -0.06 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | -0.12 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-16.75
Consensus analyst estimateRevenue Estimate
$2.25 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-16.75
Consensus analyst estimateRevenue Estimate
$2.25 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Nabriva Therapeutics Plc
39 employees
CEO: Theodore Schroeder
Nabriva Therapeutics plc is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative anti-infective medicines for managing serious infections. Its current portfolio includes SIVEXTRO, an oxazolidinone...